POLR2L Inhibitors

Chemical inhibitors of POLR2L encompass a range of compounds that directly target the mechanism of transcription by inhibiting the RNA polymerase II complex where POLR2L is a functional component. α-Amanitin exerts its inhibitory effect on POLR2L by binding directly to the RNA polymerase II enzyme, obstructing the mRNA elongation process that is crucial for gene expression. Similarly, Triptolide inhibits POLR2L activity through covalent modification of its subunits, which halts RNA polymerase II-mediated transcription. Cordycepin mimics adenosine and is incorporated into the growing mRNA chain, leading to premature termination and thereby inhibiting the elongation process facilitated by POLR2L. Actinomycin D intercalates into DNA and blocks the transcription initiation complex, preventing POLR2L from elongating mRNA. DRB achieves inhibition by obstructing the phosphorylation of the C-terminal domain of RNA polymerase II's largest subunit, an essential step in initiating transcription.

Further, Tagetitoxin, while primarily affecting RNA polymerase III, could exert an inhibitory effect on POLR2L due to the structural similarities and shared subunits between the two polymerases. Streptolydigin and Tolfenamic Acid both bind to the RNA polymerase complex and impede the mRNA chain elongation process, thereby inhibiting POLR2L function. ICRF-193 and Sobuzoxane target topoisomerase II, which is necessary for DNA unwinding during transcription; their inhibition of this enzyme can indirectly lead to POLR2L inhibition due to impeded transcriptional activity. Cantharidin inhibits protein phosphatases 1 and 2A, which are crucial for the regulation of the RNA polymerase II enzyme, resulting in the inhibition of POLR2L activity. Lastly, Flavopiridol inhibits CDK9/cyclin T, which are important for the phosphorylation of the RNA polymerase II C-terminal domain, a process that is central to the function of POLR2L in transcription.